ERIS LifescienceQ4 FY24

ERIS Lifescience Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,361.3P/E: 25.3Market Cap: ₹18.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Eris Lifesciences expects organic revenue growth of 12% to 15% in Domestic Branded Formulations for FY25, continuing the momentum seen with 15% organic growth in Q4 FY24.
  • The company is well-positioned for a diversified therapy mix driving this growth, supported by strong Diabetes portfolio including Linagliptin, Dapagliflozin combinations, and Vildagliptin in the generic space.
  • Over 20 first-in-market launches from their own R&D pipeline are anticipated, along with integration benefits from acquisitions like Biocon Injectables and Swiss Parenterals.
  • Expansion of new therapies such as Dermatology, Oncology, Nephrology, Immunology, and Insulins is expected to further contribute to secular growth.
  • Manufacturing insourcing and capacity additions (Ahmedabad plant) are planned to support revenue scaling and margin enhancement.
  • Growth in large brands and new product launches positions the company to continue outpacing market growth.

See what ERIS Lifescience management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • Eris Lifesciences intends to raise around Rs. 1,250 crores through Non-Convertible Debentures (NCDs).
  • The purpose is to repay Commercial Papers (CPs) due in first or second week of June.
  • The company plans to continue deleveraging, targeting a debt-to-EBITDA ratio of less than 2x by September 2025.
  • They plan to repay Rs. 400 crores of debt via internal accruals in FY25 and Rs. 600 crores in the following year.
  • Capex of Rs. 70-80 crores per year is planned for the next two years, mainly for manufacturing units to insource Biocon Injectables portfolio.
  • No new equity fundraising is explicitly mentioned in the disclosed sections.

See what ERIS Lifescience management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Capex of Rs. 70 to 80 crores planned annually for FY25 and FY26.
  • Investments focused on setting up manufacturing units at Ahmedabad for insourcing Biocon products, including Insulins, Oncology, and Hormones.
  • Capacity creation is needed for specialized containment units related to these therapies.
  • Emphasis on converting the Biocon Injectables portfolio in-house.
  • Investment in strengthening the production footprint to support export of oral solid dose forms and leverage Swiss Parenterals' channel.
  • Continued investment in in-house manufacturing sites (Guwahati and Ahmedabad), which currently account for around 60% of Domestic Branded Formulations revenue.
  • Strategic investment directed at business integration and new product launches, with over 20 first-in-market launches expected from the R&D pipeline.

Track ERIS Lifescience — get its next earnings analysis in your feed

How does ERIS Lifescience rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisERIS Lifescience
Rev 3Mar 3

How does ERIS Lifescience rank in Pharmaceuticals & Biotechnology?

Compare ERIS Lifescience against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →